Contents

11 Measles

References

  1. Strebel PM, Papania MJ, Fiebelkorn AP, et al. 2013. Measles vaccine. In: Plotkin SA, Orenstein WA, Offit PA (eds). Vaccines (6th edition): Elsevier Saunders.
  2. Fine PEM, Mulholland K. 2013. Community immunity. In: Plotkin SA, Orenstein WA, Offit PA (eds). Vaccines (6th edition): Elsevier Saunders.
  3. American Academy of Pediatrics. 2012. Measles. In: Pickering LK, Baker CJ, Kimberlin DW, et al (eds). Red Book: 2012 report of the Committee on Infectious Diseases (29th edition). Elk Grove Village, IL: American Academy of Pediatrics.
  4. Miller CL. 1985. Deaths from measles in England and Wales, 1970–83. British Medical Journal 290(6466): 443–4.
  5. Simons E, Ferrarri M, Fricks J, et al. 2012. Assessment of the 2010 global measles mortality reduction goal: results from a model of surveillance data. The Lancet 379(9832). DOI: 10.1016/S0140-6736(12)60522-4 (accessed 27 August 2013).
  6. Peltola H, Heinonen OP, Valle M, et al. 1994. The elimination of indigenous measles mumps and rubella from Finland by a 12-year, two dose vaccination program. New England Journal of Medicine 331(21): 1397–402.
  7. World Health Organization. 2012. Global Measles and Rubella Strategic Plan: 2012–2020. URL: www.who.int/immunization/newsroom/Measles_Rubella_StrategicPlan_2012_2020.pdf (accessed 27 August 2013).
  8. World Health Organization Western Pacific Region. 2013. Measles-Rubella Bulletin 7(9). URL: www.wpro.who.int/immunization/documents/MRBulletinVol7Issue9.pdf (accessed 1 November 2013).
  9. World Health Organization Western Pacific Region. 2013. Second Meeting of the Regional Verification Commission for Measles Elimination. URL: www.wpro.who.int/immunization/meetings/2013/rvc2/en/index.html (accessed 27 August 2013).
  10. World Health Organization. 2013. Global Vaccine Action Plan 2011–2020. URL: www.who.int/immunization/global_vaccine_action_plan/GVAP_doc_2011_2020/en/ (accessed 27 August 2013).
  11. Institute of Environmental Science and Research Ltd. 2012. Annual Summary of Outbreaks in New Zealand 2011. URL: https://surv.esr.cri.nz/PDF_surveillance/AnnualRpt/AnnualOutbreak/2011/2011OutbreakRpt.pdf (accessed 27 August 2013).
  12. Auckland Regional Public Health Service. 2012. Measles. URL: www.arphs.govt.nz/health-information/communicable-disease/measles (accessed 26 October 2013).
  13. Institute of Environmental Science and Research Ltd. 2013. Notifiable and Other Diseases in New Zealand: Annual report 2012. URL: https://surv.esr.cri.nz/PDF_surveillance/AnnualRpt/AnnualSurv/2012/2012AnnualSurvRpt.pdf (accessed 19 August 2013).
  14. Roberts MG. 2004. A Mathematical Model for Measles Vaccination. Unpublished report to the Ministry of Health, New Zealand.
  15. Zahraei SM, Gouya MM, Mokhtari Azad T, et al. 2011. Successful control and impending elimination of measles in the Islamic Republic of Iran. Journal of Infectious Diseases 204(Suppl 1): S305–11.
  16. Demicheli V, Rivetti A, Debalini MG, et al. 2012. Vaccines for measles, mumps and rubella in children. Cochrane Database of Systematic Reviews. Issue 2, Art. No. CD004407. DOI: 10.1002/14651858.CD004407.pub3 (accessed 27 August 2013).
  17. Anders JF, Jacobsen RM, Poland GA, et al. 1996. Secondary failure rate of measles vaccines: a meta-analysis of published studies. Pediatric Infectious Disease Journal 15(1): 62–6.
  18. Davidkin I, Jokinen S, Broman M, et al. 2008. Persistence of measles, mumps and rubella antibodies in an MMR vaccinated cohort: a 20-year follow-up. Journal of Infectious Diseases 197(7): 950–6.
  19. Kontio M, Jokinen S, Paunio M, et al. 2012. Waning antibody levels and avidity: implications for MMR vaccine-induced protection. Journal of Infectious Diseases 206(10): 1542–8.
  20. Ministry of Health. 2012. National Guidelines for Vaccine Storage and Distribution. URL: www.health.govt.nz/publication/national-guidelines-vaccine-storage-and-distribution-2012
  21. Centers for Disease Control and Prevention. 2005. Preventable measles among US residents, 2001–4. Morbidity and Mortality Weekly Report 54(33): 817–20.
  22. James JM, Burks W, Roberson P, et al. 1995. Safe administration of measles vaccine to children allergic to eggs. New England Journal of Medicine 332(19): 1262–6.
  23. Khakoo GA, Lack G. 2000. Recommendations for using MMR vaccine in children allergic to eggs. British Medical Journal 320(7239): 929–32.
  24. Nakayama T, Aizawa C, Kuno-Sakai H. 1999. A clinical analysis of gelatin allergy and determination of its causal relationship to the previous administration of gelatin-containing acellular pertussis vaccine combined with diphtheria and tetanus toxoids. Journal of Allergy and Clinical Immunology 103(2 Pt 1): 321–5.
  25. Peltola H, Heinonen OP. 1986. Frequency of true adverse reactions to measles-mumps-rubella vaccine. The Lancet 327(8487): 939–42.
  26. Peltola H, Patja A, Leinikki P, et al. 1998. No evidence for measles mumps and rubella vaccine-associated inflammatory bowel disease or autism in a 14 year prospective study. The Lancet 351(9112): 1327–8.
  27. Wolf J, Eisen JE, Fraimow HS. 1993. Symptomatic rubella reinfection in an immune contact of a rubella vaccine recipient. Southern Medical Journal 86(1): 91–3.
  28. Morfin F, Beguin A, Lina B, et al. 2002. Detection of measles vaccine in the throat of a vaccinated child. Vaccine 20(11–12): 1541–3.
  29. Reef SE, Plotkin SA. 2013. Rubella vaccine. In: Plotkin SA, Orenstein WA, Offit PA (eds). Vaccines (6th edition): Elsevier Saunders.
  30. O’Leary ST, Glanz JM, McClure DL, et al. 2012. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics 129(2): 248–55.
  31. Beeler J, Varricchio F, Wise R. 1996. Thrombocytopenia after immunisation with measles vaccines: review of the vaccine adverse events reporting system (1990 to 1994). Pediatric Infectious Disease Journal 15(1): 88–90.
  32. The Medicines Control Agency and Committee on the Safety of Medicines. 2001. MMR vaccine and idiopathic thrombocytopenic purpura. Current Problems in Pharmacovigilance 27: 15.
  33. Miller E, Waight P, Farrington CP, et al. 2001. Idiopathic thrombocytopenic purpura and MMR vaccine. Archives of Disease in Childhood 84(3): 227–9.
  34. Stowe J, Kafatos G, Andrews N, et al. 2008. Idiopathic thrombocytopenic purpura and the second dose of MMR. Archives of Disease in Childhood 93(2): 182–3.
  35. Weibel RE, Caserta V, Benor DE, et al. 1998. Acute encephalopathy followed by permanent brain injury or death associated with further attenuated measles vaccines: a review of claims submitted to the National Vaccine Injury Compensation Program. Pediatrics 101(3): 383–7.
  36. Black S, Shinefield H, Ray P, et al. 1997. Risk of hospitalization because of aseptic meningitis after measles-mumps-rubella vaccination in one- to two-year-old children: an analysis of the Vaccine Safety Datalink (VSD) Project. Pediatric Infectious Disease Journal 16(5): 500–3.
  37. Farrington CP, Pugh S, Colville A, et al. 1995. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. The Lancet 345(8949): 567–9.
  38. Slater PE, Ben-Zvi T, Fogel A, et al. 1995. Absence of an association between rubella vaccination and arthritis in underimmune post-partum women. Vaccine 13(16): 1529–32.
  39. Ray P, Black S, Shinefield H, et al. 1997. Risk of chronic arthropathy among women after rubella vaccination. Journal of the American Medical Association 278(7): 551–6.
  40. Tingle AJ, Mitchell LA, Grace M, et al. 1997. Randomised double-blind placebo-controlled study on adverse effects of rubella immunisation in seronegative women. Lancet 349(9061): 1277–81.
  41. Institute of Medicine. 2012. Adverse Effects of Vaccines: Evidence and causality Washington DC: The National Academies Press.
  42. Miller E. 2002. MMR vaccine: review of benefits and risks. Journal of Infection 44(1): 1–6.
  43. Makela A, Nuorti JP, Peltola H. 2002. Neurologic disorders after measles-mumps-rubella vaccination. Pediatrics 110(5): 957–63.
  44. Health Canada. 2001. Does measles-mumps-rubella (MMR) vaccination cause inflammatory bowel disease and autism? Canada Communicable Disease Report 27(8): 65–72.
  45. Davis RL, Kramarz P, Bohlke K, et al. 2001. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease. Archives of Pediatric & Adolescent Medicine 155(3): 354–9.
  46. Yang HM, Mao M, Wan CM. 2005. Vitamin A for treating measles. Cochrane Database of Systematic Reviews. Issue 4, Art. No. CD001479. DOI: 10.1002/14651858.CD001479.pub3
  47. World Health Organization. 2009. Measles vaccines: WHO position paper. Weekly Epidemiological Record (35). URL: www.who.int/wer/2009/wer8435.pdf
  48. Ministry of Health. 2012. Communicable Disease Control Manual 2012. URL: www.health.govt.nz/publication/communicable-disease-control-manual-2012